EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Case Report: Zoledronic acid-induced hyperprogression in oncology: a case study of RET-driven neuroendocrine carcinoma treated with Selpercatinib

Junqi Liu, FengJiao He

Frontiers in Oncology · 04.06.2026 · 16

DOI: 10.3389/fonc.2026.1709014 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Frontiers in Oncology, online erschienen am 04.06.2026. Verfasst von Junqi Liu und 1 weiteren Autor:innen. Beteiligte Einrichtung: Hunan Academy of Traditional Chinese Medicine, Affiliated Hospital, Changsha, China. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Selpercatinib is a highly selective RET inhibitor with potent activity in RET-driven malignancies. Zoledronic acid is a standard bone-modifying agent for bone metastases, but its potential to induce hyperprogressive disease (HPD) is unclear. We present a 59-year-old woman with neuroendocrine carcinoma of unknown primary carrying a RET p.V804M mutation and widespread metastases. She achieved partial remission for 6 months with Selpercatinib plus denosumab. After switching to zoledronic acid, she developed HPD within 1 month, with severe bone pain, sharply elevated NSE, and radiological progression. Her condition deteriorated rapidly, and she died 8 months post-diagnosis. A strong temporal correlation suggests a potential triggering role of zoledronic acid, but causality is unproven. Tumor aggressiveness and acquired resistance to Selpercatinib are plausible alternative explanations. Mechanisms involving FPPS inhibition, Ras dysregulation, and γδ T-cell activation remain speculative. This hypothesis-generating case indicates that switching bone-modifying agents during RET inhibitor therapy requires close monitoring. Further studies are needed to confirm the safety and mechanisms underlying HPD.

Schlagwörter

Stichwörter der Autor:innen

RET mutationSelpercatinibhyperprogressive diseaseneuroendocrine carcinomazoledronic acid

Autor:innen und Institutionen

  • Hunan Academy of Traditional Chinese Medicine, Affiliated Hospital, Changsha, China.

Zitieren

APA

Liu, J., & He, F. (2026). Case Report: Zoledronic acid-induced hyperprogression in oncology: a case study of RET-driven neuroendocrine carcinoma treated with Selpercatinib. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1709014

Vancouver

Liu J, He F. Case Report: Zoledronic acid-induced hyperprogression in oncology: a case study of RET-driven neuroendocrine carcinoma treated with Selpercatinib. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1709014

BibTeX
@article{Liu2026,
  author = {Liu, Junqi and He, FengJiao},
  title = {Case Report: Zoledronic acid-induced hyperprogression in oncology: a case study of RET-driven neuroendocrine carcinoma treated with Selpercatinib},
  journal = {Frontiers in Oncology},
  year = {2026},
  volume = {16},
  doi = {10.3389/fonc.2026.1709014}
}
Kostenlos starten →